Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
Stryker has received FDA 510(k) clearance for Sonopet® 3 , the latest evolution of its ultrasonic bone and soft tissue removal platform. Developed in collaboration with surgeons, Sonopet 3 delivers enhanced power, precision and versatility. Customers gain access to advanced technologies...
Covered in this story
Analyst targets on Stryker Corporation
- Truist Securities: $278 → $310 by Oct 2027 · Hold via Investing.com
- Needham: $278 → $418 by Oct 2027 · Buy via Investing.com
- Stifel: $275 → $330 by Sep 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $SYK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Stryker Corporation →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.